Selank: Tuftsin-Derived Anxiolytic Peptide Research Overview

Selank (TP-7) is a synthetic heptapeptide anxiolytic developed and studied primarily in Russia. Structurally, it is a stabilized analog of tuftsin — the naturally occurring tetrapeptide Thr-Lys-Pro-Arg found on the Fc region of immunoglobulin G. Three additional residues (Pro-Gly-Pro) were added to the C-terminus to improve metabolic stability, producing the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Selank was developed collaboratively by the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology. An important caveat for readers: the research base for Selank is dominated by Russian-language publications, and most English-indexed sources are translated abstracts or reviews. Independent Western replication is sparse. This guide accurately represents what the indexed literature contains while being explicit about those limitations.

What Is Selank?

Tuftsin is an endogenous tetrapeptide derived from proteolytic cleavage of leukokinin, a fragment of IgG heavy chain. It is known to stimulate phagocytic activity of macrophages and monocytes and has been investigated for immunomodulatory effects. Selank extends tuftsin by appending Pro-Gly-Pro to the C-terminus, producing a molecule with markedly improved plasma stability (resistant to rapid enzymatic degradation) and, according to Russian preclinical and clinical data, a distinct psychopharmacological profile characterized by anxiolytic effects without sedation.

Selank is registered as a pharmaceutical drug in Russia under the trade name Selank and is approved for use in generalized anxiety disorder and neurasthenia in that jurisdiction. It is not approved by the FDA, EMA, MHRA, or TGA. Outside Russia, it is sold as a research peptide. Its legal status in Western markets is research-use only.

Mechanism of Action

The precise mechanism of Selank's anxiolytic action has not been fully elucidated. Multiple mechanisms have been proposed and studied in preclinical models:

GABAergic modulation: A 2016 study published in Frontiers in Pharmacology (Volkova et al.) demonstrated that Selank administration affects the expression of genes involved in GABAergic neurotransmission in rat brain, suggesting a benzodiazepine-like potentiation of GABA-A receptor signaling as a contributing mechanism. BDNF upregulation: Semenova et al. (2010) and subsequent studies showed that Selank increases brain-derived neurotrophic factor (BDNF) levels in the hippocampus and prefrontal cortex in rodent models. BDNF modulation is associated with anxiolytic and antidepressant effects in animal models. Enkephalin metabolism: Early Russian work proposed that Selank inhibits the degradation of endogenous enkephalins, thereby prolonging their anxiolytic effects. Serotonin and dopamine system effects have also been reported in rodent behavioral pharmacology studies.

It is notable that several of these mechanisms have been proposed but not fully deconflicted — Selank may act through multiple pathways simultaneously, or its primary mechanism may vary by dose and administration route.

What the Research Shows

Transparency note: The majority of Selank research has been published in Russian-language journals or in journals of the former Soviet academy system. PubMed-indexed English-language publications are limited. Many cited findings are from translated abstracts. Independent replication by Western research groups is largely absent. This limits the weight of evidence considerably.

Animal behavioral studies: Multiple studies from Kozlovskaya and Semenova's research groups at the Zakusov Institute have used rodent models (elevated plus maze, open field, conflict paradigms) to document anxiolytic effects of Selank. Semenova et al. (2010) reported that Selank reduced anxiety-related behavior in rats in the context of tuftsin-family peptide comparisons. Kozlovskii and Danchev (2002) demonstrated that Selank optimized conditioned active avoidance reflex performance in stressed animals.

Memory and cognition: A study published in Bulletin of Experimental Biology and Medicine (Inozemtsev et al., 2019) demonstrated that Selank protected against ethanol-induced memory impairment in rats by regulating hippocampal and prefrontal BDNF content. This paper is English-indexed in PubMed.

Diazepam interaction: A 2017 PMC-indexed study (Semenova et al., 2017) examined whether Selank potentiates the anxiolytic effects of diazepam under chronic mild stress conditions in rats. The study reported that Selank enhanced diazepam's efficacy, which is consistent with a GABAergic modulatory mechanism.

Human clinical data: Open-label and controlled clinical investigations conducted in Russia have reported anxiolytic efficacy in generalized anxiety disorder and adjustment disorder. These studies led to Selank's pharmaceutical registration in Russia. However, they have not been published in Western peer-reviewed journals and have not been independently evaluated by the FDA, EMA, or MHRA. No Phase 2 or Phase 3 randomized controlled trials meeting Western regulatory standards have been published in English.

Pharmacokinetics

Published pharmacokinetic data for Selank in English-language peer-reviewed literature are sparse. The following parameters are derived from Russian pharmaceutical registration summaries and translated data sheets: Half-life: reported as approximately 1–2 minutes for the parent compound in plasma (rapid enzymatic degradation), with active metabolites potentially persisting longer. This is consistent with intranasal administration being the predominant route in Russian pharmaceutical use — direct delivery to the CNS bypasses first-pass systemic exposure. Administration: intranasal administration (as drops) is the registered Russian route; subcutaneous injection is used in research settings. Intranasal bioavailability to the CNS is thought to be substantially higher than systemic subcutaneous exposure relative to effective CNS concentration. Metabolism: Selank is metabolized by plasma endopeptidases to fragments including tuftsin and Pro-Gly-Pro; some metabolites may retain biological activity.

Common Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

In animal studies, Selank has been administered intraperitoneally or subcutaneously at doses in the range of 0.1–1.0 mg/kg. The Russian pharmaceutical formulation is a 0.15% intranasal solution; the registered human dose is described in Russian registration documents as 3 drops per nostril (approximately 250–300 mcg total). Subcutaneous doses used in research-community applications typically range from 250 to 500 mcg, though these are not validated by published human dose-finding studies.

Storage and Handling

Selank is supplied in research markets as a lyophilized powder or occasionally as a pre-mixed intranasal solution. Lyophilized Selank: store at −20 °C, protected from moisture and light. Reconstituted solution: store at 2–8 °C and use within 28 days. Intranasal solution (if obtained): store per manufacturer instructions, typically refrigerated at 2–8 °C. As a small peptide, Selank is susceptible to degradation at elevated temperatures; do not store reconstituted solution at room temperature.

What Selank Is NOT

Selank is not a benzodiazepine. While it may share some GABAergic modulatory activity, it does not bind the benzodiazepine binding site on GABA-A receptors in the same way and is not associated with the dependence, tolerance, or withdrawal profile of classical benzodiazepines — though this has not been studied in rigorous long-term human trials. Selank is not approved by the FDA, EMA, MHRA, or TGA for any indication. It is approved only in Russia and some CIS countries. Selank is not tuftsin. It is a structural derivative with modified stability and distinct pharmacological properties. Selank is not an SSRI or SNRI. Its mechanism differs from standard antidepressant/anxiolytic drugs, though BDNF upregulation is a mechanism shared with some antidepressant effects.

References

See citations below. Note: several foundational Selank studies by Kozlovskaya, Semenova, and Inozemtsev are published in Russian-language journals (Zhurnal Vysshei Nervnoi Deyatelnosti, Eksperimental'naya i Klinicheskaya Farmakologiya) and are accessible via PubMed as translated or English-language versions in Neuroscience and Behavioral Physiology and Bulletin of Experimental Biology and Medicine.